Treatment of interstitial lung diseases associated with connective tissue diseases

References

• Nakajima A, Inoue E, Tanaka E et al. Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA. Scand. J. Rheumatol.39, 360–367 (2010).
   PubMed Web of Science ®Google Scholar
• Maradit-Kremers H, Nicola PJ, Crowson CS et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum.52, 722–732 (2005).
   PubMed Web of Science ®Google Scholar
• Remy-Jardin M, Remy J, Cortet B, Mauri F et al. Lung changes in rheumatoid arthritis: CT findings. Radiology193, 375–382 (1994).
   PubMed Web of Science ®Google Scholar
• Walker UA, Tyndall A, Czirják L et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research Group database. Ann. Rheum. Dis.66, 754–763 (2007).
   PubMed Web of Science ®Google Scholar
• Fathi M, Vikgren J, Boijsen M et al. Interstitial lung disease in polymyositis and DM: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum.59, 677–685 (2008).
   PubMed Web of Science ®Google Scholar
• Marie I, Hachulla E, Chérin P et al. Interstitial lung disease in polymyositis and DM. Arthritis Rheum.47, 614–622 (2002).
   PubMed Web of Science ®Google Scholar
• Papathanasiou MP, Constantopoulos SH, Tsampoulas C et al. Reappraisal of respiratory abnormalities in primary and secondary Sjögren’s syndrome. A controlled study. Chest90, 370–374 (1986).
   PubMed Web of Science ®Google Scholar
• Strimlan CV, Rosenow EC 3rd, Divertie MB et al. Pulmonary manifestations of Sjögren’s syndrome. Chest70, 354–361 (1976).
   PubMed Web of Science ®Google Scholar
• Wiedemann HP, Matthay RA. Pulmonary manifestations of systemic lupus erythematosus. J. Thorac. Imaging7, 1–18 (1992).
   Google Scholar
• Weinrib L, Sharma OP, Quismorio FP Jr. A long-term study of interstitial lung disease in systemic lupus erythematosus. Semin. Arthritis Rheum.20, 48–56 (1990).
   PubMed Web of Science ®Google Scholar
• Bodolay E, Szekanecz Z, Dévényi K et al. Evaluation of interstitial lung disease in mixed connective tissue disease (MCTD). Rheumatology (Oxford)44, 656–661 (2005).
   PubMed Web of Science ®Google Scholar
• Lee HK, Kim DS, Yoo B et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest127, 2019–2027 (2005).
   PubMed Web of Science ®Google Scholar
• Highland KB, Silver RM. New developments in scleroderma interstitial lung disease. Curr. Opin. Rheumatol.17, 737–745 (2005).
   PubMedGoogle Scholar
• Parambil JG, Myers JL, Lindell RM et al. Interstitial lung disease in primary Sjögren syndrome. Chest130, 1489–1495 (2006).
   PubMed Web of Science ®Google Scholar
• Douglas WW, Tazelaar HD, Hartman TE et al. Polymyositis-DM-associated interstitial lung disease. Am. J. Respir. Crit. Care Med.164, 1182–1185 (2001).
   PubMed Web of Science ®Google Scholar
• Kanat F, Levendoglu F, Teke T. Radiological and functional assessment of pulmonary involvement in the rheumatoid arthritis patients. Rheumatol. Int.27, 459–466 (2007).
   PubMedGoogle Scholar
• Barrera P, Laan RF, van Riel PL et al. Methotrexate-related pulmonary complications in rheumatoid arthritis. Ann. Rheum. Dis.53, 434–439 (1994).
   PubMed Web of Science ®Google Scholar
• Shidara K, Hoshi D, Inoue E et al. Incidence of and risk factors for interstitial pneumonia in patients with rheumatoid arthritis in a large Japanese observational cohort, IORRA. Mod. Rheumatol.20, 280–286 (2010).
   PubMed Web of Science ®Google Scholar
• Tokuda H, Sakai F, Yamada H et al. Clinical and radiological features of pneumocystis pneumonia in patients with rheumatoid arthritis, in comparison with methotrexate pneumonitis and pneumocystis pneumonia in acquired immunodeficiency syndrome: a multicenter study. Intern. Med.47, 915–923 (2008).
   PubMed Web of Science ®Google Scholar
• Olsen NJ, Park JH, King LE Jr. Amyopathic DM. Curr. Rheumatol. Rep.3, 346–351 (2001).
   PubMedGoogle Scholar
• Koyama M, Johkoh T, Honda O et al. Pulmonary involvement in primary Sjögren’s syndrome: spectrum of pulmonary abnormalities and computed tomography findings in 60 patients. J. Thorac. Imaging16, 290–296 (2001).
   PubMed Web of Science ®Google Scholar
• Cottin V, Nunes H, Brillet PY et al.; Groupe d’Etude et de Recherche sur les Maladies Orphelines Pulmonaires (GERM O P). Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur. Respir. J.26, 586–593 (2005).
   PubMed Web of Science ®Google Scholar
• Cottin V, Nunes H, Mouthon L et al.; Groupe d’Etudes et de Recherche sur les Maladies ‘Orphelines’ Pulmonaires. Combined pulmonary fibrosis and emphysema syndrome in connective tissue disease. Arthritis Rheum.63, 295–304 (2011).
   PubMed Web of Science ®Google Scholar
• Raghu G, Collard HR, Egan JJ et al.; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. J. Respir. Crit. Care Med.183, 788–824 (2011).
   PubMed Web of Science ®Google Scholar
• Nanki N, Fujita J, Yamaji Y et al. Nonspecific interstitial pneumonia/fibrosis completely recovered by adding cyclophosphamide to corticosteroids. Intern. Med.41, 867–870 (2002).
   Google Scholar
• Chang HK, Park W, Ryu DS. Successful treatment of progressive rheumatoid interstitial lung disease with cyclosporine: a case report. J. Korean Med. Sci.17, 270–273 (2002).
   PubMed Web of Science ®Google Scholar
• Cohen JM, Miller A, Spiera H. Interstitial pneumonitis complicating rheumatoid arthritis. Sustained remission with azathioprine therapy. Chest72, 521–524 (1977).
   Google Scholar
• DeMarco PJ, Weisman MH, Seibold JR et al. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum.46, 2983–2989 (2002).
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Elashoff R, Clements PJ et al.; Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med.354, 2655–2666 (2006).
   PubMed Web of Science ®Google Scholar
• Hoyles RK, Ellis RW, Wellsbury J et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum.54, 3962–3970 (2006).
   PubMed Web of Science ®Google Scholar
• Zamora AC, Wolters PJ, Collard HR et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir. Med.102, 150–155 (2008).
   PubMed Web of Science ®Google Scholar
• Gerbino AJ, Goss CH, Molitor JA. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest133, 455–460 (2008).
   PubMed Web of Science ®Google Scholar
• Nadashkevich O, Davis P, Fritzler M et al. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin. Rheumatol.25, 205–212 (2006).
   PubMed Web of Science ®Google Scholar
• Bérezné A, Ranque B, Valeyre D et al. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. J. Rheumatol.35, 1064–1072 (2008).
   PubMed Web of Science ®Google Scholar
• de Clerck LS, Dequeker J, Francx L et al.D-penicillamine therapy and interstitial lung disease in scleroderma. A long-term followup study. Arthritis Rheum.30, 643–650 (1987).
   PubMedGoogle Scholar
• Steen VD, Owens GR, Redmond C et al. The effect of D-penicillamine on pulmonary findings in systemic sclerosis. Arthritis Rheum.28, 882–888 (1985).
   PubMedGoogle Scholar
• Clements PJ, Furst DE, Wong WK et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum.42, 1194–1203 (1999).
   PubMed Web of Science ®Google Scholar
• Guttadauria M, Diamond H, Kaplan D. Colchicine in the treatment of scleroderma. J. Rheumatol.4, 272–276 (1977).
   Google Scholar
• Schachna L, Medsger TA Jr, Dauber JH et al. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum.54, 3954–3961 (2006).
   PubMed Web of Science ®Google Scholar
• Goh NS, Desai SR, Veeraraghavan S et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am. J. Respir. Crit. Care Med.177, 1248–1254 (2008).
   PubMed Web of Science ®Google Scholar
• Takada K, Nagasaka K, Miyasaka N. Polymyositis/DM and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity38, 383–392 (2005).
   PubMed Web of Science ®Google Scholar
• Ochi S, Nanki T, Takada K et al. Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/DM. Clin. Exp. Rheumatol.23, 707–710 (2005).
   PubMed Web of Science ®Google Scholar
• Wilkes MR, Sereika SM, Fertig N et al. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum.52, 2439–2446 (2005).
   PubMed Web of Science ®Google Scholar
• Qushmaq KA, Chalmers A, Esdaile JM. Cyclosporin A in the treatment of refractory adult polymyositis/DM: population based experience in 6 patients and literature review. J. Rheumatol.27, 2855–2859 (2000).
   PubMed Web of Science ®Google Scholar
• Maeda K, Kimura R, Komuta K et al. Cyclosporine treatment for polymyositis/DM: is it possible to rescue the deteriorating cases with interstitial pneumonitis? Scand. J. Rheumatol.26, 24–29 (1997).
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Hayakawa H, Miwa S et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/DM. Lung187, 201–206 (2009).
   PubMed Web of Science ®Google Scholar
• Deheinzelin D, Capelozzi VL, Kairalla RA et al. Interstitial lung disease in primary Sjögren’s syndrome. Clinical-pathological evaluation and response to treatment. Am. J. Respir. Crit. Care Med.154(3 Pt 1), 794–799 (1996).
   PubMed Web of Science ®Google Scholar
• Swigris JJ, Olson AL, Fischer A et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest130, 30–36 (2006).
   PubMed Web of Science ®Google Scholar
• Weinrib L, Sharma OP, Quismorio FP Jr. A long-term study of interstitial lung disease in systemic lupus erythematosus. Semin. Arthritis Rheum.20, 48–56 (1990).
   PubMed Web of Science ®Google Scholar
• Nakano M, Hasegawa H, Takada T et al. Pulmonary diffusion capacity in patients with systemic lupus erythematosus. Respirology7, 45–49 (2002).
   PubMedGoogle Scholar
• Lindsay K, Melsom R, Jacob BK et al. Acute progression of interstitial lung disease: a complication of etanercept particularly in the presence of rheumatoid lung and methotrexate treatment. Rheumatology (Oxford)45, 1048–1049 (2006).
   PubMed Web of Science ®Google Scholar
• Ostor AJ, Crisp AJ, Somerville MF et al. Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab. BMJ329, 1266 (2004).
   PubMed Web of Science ®Google Scholar
• Vassallo R, Matteson E, Thomas CF Jr. Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition. Chest122, 1093–1096 (2002).
   PubMedGoogle Scholar
• Cornec D, Avouac J, Youinou P et al. Critical analysis of rituximab-induced serological changes in connective tissue diseases. Autoimmun. Rev.8, 515–519 (2009).
   PubMed Web of Science ®Google Scholar
• Okamoto H, Kamatani N. Rituximab for rheumatoid arthritis. N. Engl. J. Med.351, 1909 (2004).
   PubMedGoogle Scholar
• Yoo WH. Successful treatment of steroid and cyclophosphamide-resistant diffuse scleroderma-associated interstitial lung disease with rituximab. Rheumatol. Int. doi:10.1007/s00296-009-1347-z (2010) (Epub ahead of print).
   Google Scholar
• Daoussis D, Liossis SN, Tsamandas AC et al. Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature. Semin. Arthritis Rheum.40, 127–136 (2010).
   PubMed Web of Science ®Google Scholar
• Daoussis D, Liossis SN, Tsamandas AC et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford)49, 271–280 (2010).
   PubMed Web of Science ®Google Scholar
• Lafyatis R, Kissin E, York M et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum.60, 578–583 (2009).
   PubMed Web of Science ®Google Scholar
• Rios Fernández R, Callejas Rubio JL, Sánchez Cano D et al. Rituximab in the treatment of DM and other inflammatory myopathies. A report of 4 cases and review of the literature. Clin. Exp. Rheumatol.27, 1009–1016 (2009).
   PubMed Web of Science ®Google Scholar
• King TE Jr, Behr J, Brown KK et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med.177, 75–81 (2008).
   PubMed Web of Science ®Google Scholar
• Silver RM. Endothelin and scleroderma lung disease. Rheumatology (Oxford)47(Suppl 5), v25–v26 (2008).
   Google Scholar
• Azuma A, Nukiwa T, Tsuboi E et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med.171, 1040–1047 (2005).
   PubMed Web of Science ®Google Scholar
• Nagai S, Hamada K, Shigematsu M et al. Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern. Med.41, 1118–1123 (2002).
   PubMed Web of Science ®Google Scholar
• Okamoto H, Kobayashi A. Tyrosine kinases in rheumatoid arthritis. J. Inflamm.8, 21 (2011).
   Google Scholar
• Okamoto H, Yoshio T, Kaneko H et al. Inhibition of NF-kappaB signaling by fasudil as a potential therapeutic strategy for rheumatoid arthritis. Arthritis Rheum.62, 82–92 (2010).
   PubMed Web of Science ®Google Scholar
• Rosenbloom J, Jiménez SA. Molecular ablation of transforming growth factor beta signaling pathways by tyrosine kinase inhibition: the coming of a promising new era in the treatment of tissue fibrosis. Arthritis Rheum.58, 2219–2224 (2008).
   PubMedGoogle Scholar
• Khanna D, Saggar R, Mayes MD et al. A one-year, Phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum.63, 3540–3546 (2011).
   PubMed Web of Science ®Google Scholar
• Richeldi L, Costabel U, Selman M et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N. Engl. J. Med.365, 1079–1087 (2011).
   PubMed Web of Science ®Google Scholar
• Okamoto H, Hoshi D, Kiire A et al. Molecular targets of rheumatoid arthritis. Inflamm. Allergy Drug Targets7, 53–66 (2008).
   PubMedGoogle Scholar
• Okamoto H. Molecular aspects of rheumatoid arthritis: chemokines, environmental factors and transcription factors. FEBS J.275, 4447 (2008).
   Google Scholar